Lonza Stock Bounces Back as Biopharma Pipeline Drives Recovery

Lonza Group's stock is in a transition phase as investors weigh its weaker 2023 earnings base against its multi-year biopharma pipeline. The company's sales declined to CHF 6.7 billion from roughly CHF 6.2 billion in 2022, while margins and profit were pressured by portfolio changes and normalizing post-pandemic demand.

The biopharma segment remains the growth engine for Lonza, accounting for a majority of group sales in 2023. The company's focus on large-scale biologics manufacturing and development services drives capital expenditure, with commitments of several hundred million Swiss francs annually to expand fermentation, mammalian cell culture, and fill-and-finish capacity.

Lonza's reported core EBITDA margin eased compared to the strong levels seen during the pandemic-driven vaccine and biologics demand peak. The company faces competition from other global CDMOs and in-house pharma manufacturing capabilities, keeping pricing and margin discipline essential.